Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension

Respiratory Medicine

Volumn 102, Issue 7, 2008, Pages 1073-1079

  JunHui, Zhu ^a   XingXiang, Wang ^b   GuoSheng, Fu ^a   YunPeng, Shang ^b   FuRong, Zhang ^b   JunZhu, Chen ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Angiogenesis; Endothelial progenitor cells; Endothelium; Idiopathic pulmonary arterial hypertension; Stem cells

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; FIBRONECTIN; HOMOCYSTEINE; INTERLEUKIN 6; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CELL ADHESION; CELL MIGRATION; CELL STRUCTURE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; FEMALE; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY HYPERTENSION; STEM CELL;

ADULT; CELL ADHESION; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; EXERCISE TEST; FEMALE; FLOW CYTOMETRY; HUMANS; HYPERTENSION, PULMONARY; MALE; STEM CELLS; WALKING;

EID: 44649145119     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2007.12.030     Document Type: Article

References (46)

1. Barst R.J., Rubin L.J., Long W.A., et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy in primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 334 (1996) 296-301
2. Rubin L.J., Badesch D.B., Barst R.J., et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346 (2002) 896-903
3. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
4. Barst R.J. PDGF signaling in pulmonary arterial hypertension. J Clin Invest 115 (2005) 2691-2694
5. Abramowicz M.J., Van Haecke P., Demedts M., and Delcroix M. Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation. Eur Respir J 22 (2003) 560-562
6. Rich S., Rubin L., Walker A.M., Schneeweiss S., and Abenhaim L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. Chest 117 (2000) 870-874
7. Schaiberger P.H., Kennedy T.C., Miller F.C., Gal J., and Petty T.L. Pulmonary hypertension associated with long-term inhalation of "crank" methamphetamine. Chest 104 (1993) 614-616
8. Deng Z., Morse J.H., Slager S.L., et al. Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene. Am J Hum Genet 67 (2000) 737-744
9. Newman J.H., Trembath R.C., Morse J.A., et al. Genetic basis of pulmonary arterial hypertension: current understanding and future directions. J Am Coll Cardiol 43 (2004) 33S-39S
10. Kimura N., Matsuo R., Shibuya H., Nakashima K., and Taga T. BMP2-induced apoptosis is mediated by activation of the TAK1-p38 kinase pathway that is negatively regulated by Smad6. J Biol Chem 275 (2000) 17647-17652
11. West J., Fagan K., Steudel W., et al. Pulmonary hypertension in transgenic mice expressing a dominant-negative BMPRII gene in smooth muscle. Circ Res 94 (2004) 1109-1114
12. Lee S.D., Shroyer K.R., Markham N.E., Cool C.D., Voelkel N.F., and Tuder R.M. Monoclonal endothelial cell proliferation is present in primary but not secondary pulmonary hypertension. J Clin Invest 101 (1998) 927-934
13. Rubin L.J. Pulmonary arterial hypertension. Proc Am Thorac Soc 3 (2006) 111-115
14. Humbert M., Morrell N.W., Archer S.L., et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43 (2004) 13S-24S
15. Runo J.R., and Loyd J.E. Primary pulmonary hypertension. Lancet 361 (2003) 1533-1544
16. Tuder R.M., Cool C.D., Yeager M., Taraseviciene-Stewart L., Bull T.M., and Voelkel N.F. The pathobiology of pulmonary hypertension. Endothelium Clin Chest Med 22 (2001) 405-418
17. Hill J.M., Zalos G., Halcox J.P., et al. Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 348 (2003) 593-600
18. Walter D.H., Rittig K., Bahlmann F.H., et al. Statin therapy accelerate reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation 105 (2002) 3017-3024
19. Asahara T., Murohara T., Sullivan A., et al. Isolation of putative endothelial progenitor cells for angiogenesis. Science 275 (1997) 964-967
20. Peichev M., Naiyer A.J., Pereira D., et al. Expression of VEGFR-2 and AC133 by circulating human CD34 (+) cells identifies a population of functional endothelial precursors. Blood 95 (2000) 952-958
21. Gill M., Dias S., Hattori K., et al. Vascular trauma induces rapid but transient mobilization of VEGFR2+AC133+ endothelial precursor cells. Circ Res 88 (2001) 167-174
22. Rafii S. Circulating endothelial precursors: mystery, reality, and promise. J Clin Invest 105 (2000) 17-19
23. Szmitko P.E., Fedak P.W., Weisel R.D., Stewart D.J., Kutryk M.J., and Verma S. Endothelial progenitor cells: new hope for a broken heart. Circulation 107 (2003) 3093-3100
24. Kocher A.A., Schuster M.D., Szabolcs M.J., et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 7 (2001) 430-436
25. Takahashi T., Kalka C., Masuda H., et al. Ischemia- and cytokine-induced mobilization of bone marrow-derived endothelial progenitor cells for neovascularization. Nat Med 5 (1999) 434-438
26. Asahara T., Masuda H., Takahashi T., et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85 (1999) 221-228
27. Nagaya N., Kangawa K., Kanda M., et al. Hybrid cell-gene therapy for pulmonary hypertension based on phagocytosing action of endothelial progenitor cells. Circulation 108 7 (2003) 889-895
28. Zhao Y.D., Courtman D.W., Deng Y., Kugathasan L., Zhang O., and Stewart D.J. Rescue of monocrotaline-induced pulmonary arterial hypertension using bone marrow-derived endothelial-like progenitor cells: efficacy of combined cell and eNOS gene therapy in established disease. Circ Res 96 (2005) 442-450
29. Takahashi M., Nakamura T., Toba T., Kajiwara N., Kato H., and Shimizu Y. Transplantation of endothelial progenitor cells into the lung to alleviate pulmonary hypertension in dogs. Tissue Eng 10 (2004) 771-779
30. Rich S., Dantzker D.R., Ayres S.M., et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 107 (1987) 216-223
31. ATS Committee on Proficiency Standards for Clinical Pulmonary Function Laboratories. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 (2002) 111-117
32. Rubens C., Ewert R., Halank M., Wensel R., Orzechowski H.D., Schultheiss H.P., et al. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 120 5 (2001) 1562-1569
33. Vasa M., Fichtlscherer S., Aicher A., et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 89 (2001) E1-E7
34. Kalka C., Masuda H., Takahashi T., et al. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97 (2000) 3422-3427
35. Chen J.Z., Zhu J.H., Wang X.X., et al. Effects of homocysteine on number and activity of endothelial progenitor cells from peripheral blood. J Mol Cell Cardiol 36 (2004) 233-239
36. Strehlow K., Werner N., Berweiler J., et al. Estrogen increases bone marrow-derived endothelial progenitor cell production and diminishes neointima formation. Circulation 107 24 (2003) 3059-3065
37. Rehman J., Li J., Parvathaneni L., et al. Exercise acutely increases circulating endothelial progenitor cells and monocyte-/macrophage-derived angiogenic cells. J Am Coll Cardiol 43 (2004) 2314-2318
38. Zhu J.H., Wang X.X., Chen J.Z., Sun J., and Zhang F.R. Profoundly reduced number and activity of circulating endothelial progenitor cells from patients with hyperhomocysteinemia. Arch Med Res 37 (2006) 484-489
39. Shipchandler M.T., and Moore E.G. Rapid, fully automated measurement of plasma homocyst(e)ine with the Abbott IMx analyzer. Clin Chem 41 (1995) 991-994
40. Shang Y.P., Lai L., Chen J., Zhang F., and Wang X. Effects of percutaneous balloon mitral valvuloplasty on plasma B-type natriuretic peptide in rheumatic mitral stenosis with and without atrial fibrillation. J Heart Valve Dis 14 (2005) 453-459
41. Wang X.X., Zhang F.R., Shang Y.P., Zhu J.H., Xie X.D., Tao Q.M., et al. Transplantation of autologous endothelial progenitor cells may be beneficial in patients with idiopathic pulmonary arterial hypertension: a pilot randomized controlled trial. J Am Coll Cardiol 49 (2007) 1566-1571
42. Tuder R.M., Chacon M., Alger L., et al. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: evidence for a process of disordered angiogenesis. J Pathol 195 (2001) 367-374
43. George J., Herz I., Goldstein E., et al. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 23 (2003) e57-e60
44. Verma S., Kuliszewski M.A., Li S.H., et al. Creactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation 109 (2004) 2058-2067
45. Suh W., Kim K.L., Choi J.H., et al. C-reactive protein impairs angiogenic functions and decreases the secretion of arteriogenic chemo-cytokines in human endothelial progenitor cells. Biochem Biophys Res Commun 321 (2004) 65-71
46. Arroliga A.C., Sandur S., Jacobsen D.W., et al. Association between hyperhomocysteinemia and primary pulmonary hypertension. Respir Med 97 (2003) 825-829